Cumberland Pharmaceuticals Inc.
CPIXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeCumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company carries a $117.6M market cap, placing it firmly in the micro-cap category. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Market Cap
$117.6M
Beta
0.10
P/E (TTM)
—
P/E (Fwd)
56.07
EPS (TTM)
$-0.53
EPS (Fwd)
$0.14
ROE
-29.8%
ROA
-6.4%
Cash
$11.0M
Total Debt
$10.1M
Free CF
$4.9M
52W Change
130.9%
Annual Financials
Cash vs Debt
Where CPIX stands vs its 150-day and 200-day moving averages
As of the July 10, 2026 close, CPIX finished 41.78% above its 150-day moving average ($4.26) and 54.48% above its 200-day moving average ($3.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CPIX overbought or oversold?
At the July 10, 2026 close, CPIX's RSI(14) was 55.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $11.0M in cash comfortably exceeding the $10.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $4.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -29.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $42.0M (2022) to $44.5M (2025).
CPIX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cumberland Pharmaceuticals Inc.'s trajectory.